Interaction of endothelial nitric oxide and angiotensin in the circulation

Pharmacological Reviews

Volumn 59, Issue 1, 2007, Pages 54-87

  Toda, Noboru ^a,b   Ayajiki, Kazuhide ^a   Okamura, Tomio ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Toyama Institute for Cardiovascular Pharmacology Research   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; A 779; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN[1-7]; AVE 0991; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; CGS 24592; CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; INDOMETACIN; LISINOPRIL; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PHENTOLAMINE; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE B; TELMISARTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLOOD PRESSURE; CORONARY ARTERY BLOOD FLOW; CORONARY VASCULAR RESISTANCE; DIABETES MELLITUS; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; FOREARM BLOOD FLOW; GENE TARGETING; HEART MUSCLE; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY VASCULAR RESISTANCE; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASODILATATION;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CORONARY CIRCULATION; HUMANS; MODELS, BIOLOGICAL; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; RECEPTORS, ANGIOTENSIN; VASODILATION;

EID: 33847385394     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.59.1.2     Document Type: Review

References (341)

1. 2-receptor-null mice. Hypertension 42:600-604.
2. Abassi ZA, Gurbanov K, Mulroney SE, Potlog C, Opgenorth TJ, Hoffman A, Haramati A, and Winaver J (1997) Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure: role of angiotensin II. Circulation 96:3655-3664.
3. Adams V, Linke A, Krankel N, Erbs S, Gielen S, Mobius-Winkler S, Gummert JF, Mohr FW, Schuler G, and Hambrecht R (2005) Impact of regular physical activity on the NAD(P)H oxidase and angiotensin receptor system in patients with coronary artery disease. Circulation 111:555-562.
4. 1- aderenoceptors on renal hemodynamics in healthy and acute renal failure rats: the role of nitric oxide. Blood Press 10:238-246.
5. Aki Y, Tomohiro A, Nishiyama A, Kiyomoto K, Kimura S, and Abe Y (1997) The role of basally synthesized nitric oxide in modulating the renal vasoconstrictor action of angiotensin II. Hypertension Res 20:251-256.
6. Alvarez A, Hermenegildo C, Issekutz AC, Esplugues JV, and Sanz MJ (2002) Estrogens inhibit angiotensin II-induced leukocyte-endothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygenase activation. Circ Res 91:1142-1150.
7. Alvarez A, Piqueras L, Blazquez MA, and Sanz MJ (2001) Cyclic AMP elevating agents and nitric oxide modulate angiotensin II-induced leukocyte-endothelial cell interactions in vivo. Br J Pharmacol 133:485-494.
8. 1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 35:1726-1731.
9. 1 receptors through a nitric oxide- and PhoA-dependent mechanism resulting in decreased phospholipase D activity. Am J Physiol 288:F763-F770.
10. Arima S, Endo Y, Yaoita H, Omata K, Ogawa S, Tsunoda K, Abe M, Takeuchi K, Abe K, and Ito S (1997) Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J Clin Investig 100:2816-2823.
11. 2 receptor-mediated relaxation in diabetic rat thoracic aorta. J Hypertens 22:2143-2152.
12. Baan J Jr, Chang PC, Vermeij P, Pfaffendorf M, and van Zwieten PA (1997) Influence of indomethacin and L-NMMA on vascular tone and angiotensin II-induced vasoconstriction in the human forearm. Blood Press 6:279-285.
13. Badzynska B, Grzelec-Mojzesowicz M, and Sadowski J (2003) Prostaglandins but not nitric oxide protect renal medullary perfusion in anaesthetized rats receiving angiotensin II. J Physiol (Lond) 548:875-880.
14. Badzynska B, Grzelec-Mojzesowicz M, and Sadowski J (2004) Effect of exogenous angiotensin II on renal tissue nitric oxide and intrarenal circulation in anaesthetized rats. Acta Physiol Scand 182:313-318.
15. 2 receptors in the rat. Regul Pept 124:7-17.
16. 1 angiotensin II receptor-mediated vasodilatation of porcine pial arteries and arterioles. Eur J Pharmacol 525:112-116.
17. Barsotti A, Di Napoli P, Taccardi AA, Spina R, Stuppia L, Palka G, Barbacane RC, De Caterina R, and Conti P (2001) MK-954 (losartan potassium) exerts endothelial protective effects against reperfusion injury: evidence of an e-NOS mRNA overexpression after global ischemia. Atherosclerosis 155:53-59.
18. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR, and Danser AH (2004) Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 109:2296-2301.
19. Bayraktutan U, and Ulker S (2003) Effects of angiotensin II on nitric oxide generation in proliferating and quiescent rat coronary microvascular endothelial cells. Hypertens Res 26:749-757.
20. Beierwaltes WH (2006) cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3. Am J Physiol 290:F797-F805.
21. 1 receptor antagonism parallels improved vascular morphology in hypertensive rats. J Am Soc Nephrol 10(Suppl 11):S104-S115.
22. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, and Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 43:993-1002.
23. Benter IF, Diz DI, and Ferrario CM (1993) Cardiovascular actions of angiotensin (1-7). Peptides 14:679-684.
24. Benter IF, Yousif MHM, Anim JT, Cojocel C, and Diz DI (2006) Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol 290:H684-H691.
25. 2 receptors. Circ Res 94:1623-1629.
26. Berthold H, Just A, Kirchheim HR, and Ehmke H (1999) Interaction between nitric oxide and endogenous vasoconstrictors in control of renal blood flow. Hypertension 34:1254-1258.
27. Boger RH, Schwedhelm E, Maas R, Quispe-Bravo S, and Skamira C (2005) ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study. Vasc Med 10(Suppl 1):S97-S102.
28. 2 receptor-deficient mice. Hypertension 42:1177-1182.
29. Bredt DS, Hwang PM, and Snyder SH (1990) Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature (Lond) 351:768-770.
30. Brosnihan KB, Li P, and Ferrario CM (1996) Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27:523-528.
31. Brosnihan KB, Li P, Tallant EA, and Ferrario CM (1998) Angiotensin-(1-7): a novel vasodilator of the coronary circulation. Biol Res 31:227-234.
32. Brown NJ, Muldowney JA 3rd, and Vaughan DE (2006) Endogenous NO regulates plasminogen activator inhibitor-1 during angiotensin-converting enzyme inhibition. Hypertension 47:441-448.
33. Bucher M, Hobbhahn J, and Kurtz A (2001) Nitric oxide-dependent down-regulation of angiotensin II type 2 receptors during experimental sepsis. Crit Care Med 29:1750-1755.
34. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, and Weston AH (2002) EDHF: bringing the concepts together. Trends Pharmacol Sci 23:374-380.
35. Butler R, Morris AD, and Struthers AD (2001) Lisinopril improves endothelial function in chronic cigarette smokers. Clin Sci 101:53-58.
36. 2 receptors in the mouse heart. Hypertension 46:937-942.
37. Cervenka L, Kramer HJ, Maly J, and Heller J (2001) Role of nNOS in regulation of renal function in angiotensin II-induced hypertension. Hypertension 38:280-285.
38. 2 receptor knockout mice. Hypertension 37:967-973.
39. Chaki S, and Inagami T (1993) New signaling mechanism of angiotensin II in neuroblastoma neuro-2A cells: activation of soluble guanylyl cyclase via nitric oxide synthesis. Mol Pharmacol 43:603-608.
40. Champion HC, Bivalacqua TJ, D'Souza FM, Oritz LA, Jeter JR, Toyoda K, Heistad DD, Hyman AL, and Kadowitz PJ (1999) Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo: effect on agonist-induced and flow-mediated vascular responses. Circ Res 84:1422-1432.
41. Chappell MC, Diz DI, Yunis C, and Ferrario CM (1998) Differential actions of angiotensin-(1-7) in the kidney. Kidney Int Suppl 68:S3-S6.
42. Chatziantoniou C, Pauti MD Pinet F, Promeneur D, Dussaule JC, and Ardaillou R (1996) Regulation of renin release is impaired after nitric oxide inhibition. Kidney Int 49:626-633.
43. Chaytor AT, Evans WH, and Griffith TM (1998) Central role of heterocellular gap junctional communication in endothelium-dependent relaxations of rabbit arteries. J Physiol (Lond) 508:561-573.
44. Chen G, Suzuki H, and Weston AH (1988) Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol 95:1165-1174.
45. Chen JW, Hsu NW, Wu TC, Lin SJ, and Chang MS (2002) Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 90:974-982.
46. Chen S, Patel JM, and Block ER (2000) Angiotensin IV-mediated pulmonary artery vasorelaxation is due to endothelial intracellular calcium release. Am J Physiol 279:L849-L856.
47. Chen X, Minatoguchi S, Wang N, Arai M, Lu C, Uno Y, Misao Y, Takemura G, and Fujiwara H (2003) Quinaprilat reduces myocardial infarct size involving nitric oxide production and mitochondrial KATP channel in rabbits. J Cardiovasc Pharmacol 41:938-945.
48. Chin SY, Wang CT, Majid DS, and Navar LG (1998) Renoprotective effects of nitric oxide in angiotensin II-induced hypertension in the rat. Am J Physiol. 274:F876-F882.
49. Chodobski A, Szmydynger-Chodobska J, and Johanson CE (1999) Angiotensin II regulates choroid plexus blood flow by interacting with the sympathetic nervous system and nitric oxide. Brain Res 816:518-526.
50. Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE, and McMurray J (1992) Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol 19:330-340.
51. Chu ZM, and Beilin LJ (1993) Nitric oxide-mediated changes in vascular reactivity in pregnancy in spontaneously hypertensive rats. Br J Pharmacol 110:1184-1188.
52. Clayton JS, Clark KI, Johns EJ, and Drew GM (1998) Effects of prostaglandins and nitric oxide on the renal effects of angiotensin II in the anaesthetized rat. Br J Pharmacol 124:1467-1474.
53. Coleman JK, Krebs LT, Hamilton TA, Ong B, Lawrence KA, Sardinia MF, Harding JW, and Wright JW (1998) Autoradiographic identification of kidney angiotensin IV binding sites and angiotensin IV-induced renal cortical blood flow changes in rats. Peptides 19:269-277.
54. Cosentino F, Savoia C, De Paolis P, Francia P, Russo A, Maffei A, Venturelli V, Schiavoni M, Lembo G, and Volpe M (2005) Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. Am J Hypertens 18:493-499.
55. Coto E, Rodrigo L, Alvarez R, Fuentes D, Rodriguez M, Menendez LG, Ciriza C, Gonzalez P, and Alvarez V (2001) Variation at the angiotensin-converting enzyme and endothelial nitric oxide synthase genes is associated with the risk of esophageal varices among patients with alcoholic cirrhosis. J Cardiovasc Pharmacol 38:833-839.
56. Creager MA and Roddy MA (1994) Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 24:499-505.
57. w-nitro- L-arginine methyl estertreated spontaneously hypertensive rats. J Cardiovasc Pharmacol 40:789-800.
58. 2 receptor associate with nitric-oxide synthase pathway. J Pharmacol Exp Ther 311:394-401.
59. de Graeff PA and van Gilst WH (1992) The effect of bradykinin on coronary flow and its potentiation by SH-containing ACE-inhibitors. Agents Actions Suppl 38:110-118.
60. De Matteo R and May CN (1997) Glucocorticoid-induced renal vasodilatation is mediated by a direct renal action involving nitric oxide. Am J Physiol 273:R1972-R1979.
61. De Nicola L, Thomson SC, Wead LM, Brown MR, and Gabbai FB (1993) Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Investig 92:1859-1865.
62. Deja MA, Golba KS, Widenka K, Mrozek R, Biernat J, Kolowca M, Malinowski M, and Wos S (2005) Angiotensin-converting enzyme inhibitors reveal non-NO, nonprostacyclin-mediated endothelium-dependent relaxation in internal thoracic artery of hypertensive patients. Int J Cardiol 102:455-460.
63. Delles C, Jacobi J, John S, Fleischmann I, and Schmieder RE (2002) Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int 61:1462-1468.
64. Delles C, Klingbeil AU, Schneider MP, Handrock R, Schaufele T, and Schmieder RE (2004) The role of nitric oxide in the regulation of glomerular haemodynamics in humans. Nephrol Dial Transplant 19:1392-1397.
65. Delles C, Michelson G, Harazny J, Oehmer S, Hilgers KF, and Schmieder RE (2004) Impaired endothelial function of the retinal vasculature in hypertensive patients. Stroke 35:1289-1293.
66. Demeilliers B, Mimran A, and Jover B (1999) Nitric oxide participates in the renal vasodilatory effect of candesartan in anesthetized rats. J Am Soc Nephrol 10(Suppl 11):S208-S212.
67. Deng A, Miracle CM, Suarez JM, Lortie M, Satriano J, Thomson SC, Munger KA, and Blantz RC (2005) Oxygen consumption in the kidney: effects of nitric oxide synthase isoforms and angiotensin II. Kidney Int 68:723-730.
68. Deng X, Welch WJ, and Wilcox CS (1996) Role of nitric oxide in short-term and prolonged effects of angiotensin II on renal hemodynamics. Hypertension 27:1173-1179.
69. Didion SP and Faraci FM (2003) Angiotensin II produces superoxide-mediated impairment of endothelial function in cerebral arterioles. Stroke 34:2038-2042.
70. Dijkhorst-Oei LT, Beutler JJ, Stroes ES, Koomans HA, and Rabelink TJ (1998) Divergent effects of ACE-inhibition and calcium channel blockade on NO-activity in systemic and renal circulation in essential hypertension. Cardiovasc Res 40:402-409.
71. Dijkhorst-Oei LT, Stroes ED, Koomans HA, and Rabelink TJ (1999) Acute simultaneous stimulation of nitric oxide and oxygen radicals by angiotensin II in humans in vivo. J Cardiovasc Pharmacol 33:420-424.
72. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, and Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature (Lond) 399:601-605.
73. Drexler H, Kurz S, Jeserich M, Munzel T, and Hornig B (1995) Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Am J Cardiol 76:13E-18E.
74. Dukacz SA, Feng MG, Yang LF, Lee RM, and Kline RL (2001) Abnormal renal medullary response to angiotensin II in SHR is corrected by long-term enalapril treatment. Am J Physiol 280:R1076-R1084.
75. 2 receptors mediate tonic renal medullary vasoconstriction in renovascular hypertension. Br J Pharmacol 144:486-492.
76. Egi Y, Matsumura Y, Miura A, Murata S, and Morimoto S (1995) Interaction between nitric oxide and angiotensin II on antidiuresis and norepinephrine overflow induced by stimulation of renal nerves in anesthetized dogs. J Cardiovasc Pharmacol 25:187-193.
77. Ehring T, Baumgart D, Krajcar M, Hummelgen M, Kompa S, and Heusch G (1994) Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide. Circulation 90:1368-1385.
78. Erdos EG, Jackman HL, Brovkovych V, Tan F, and Deddish PA (2002) Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J Mol Cell Cardiol 34:1569-1576.
79. Evans RG, Rankin AJ, and Anderson WP (1994) Interactions of blockade of nitric oxide synthase and angiotensin-converting enzyme on renal function in conscious rabbits. J Cardiovasc Pharmacol 24:542-551.
80. Ewert S, Laesser M, Johansswon B, Holm M, Aneman A, and Fandriks L (2003) The angiotensin II receptor type 2 agonist CGP 42112A stimulates NO production in the porcine jejunal mucosa. BMC Pharmacol 3:2.
81. w-nitro-L-arginine methyl ester, LY83583, glybenclamide and L158809 on pulmonary circulation. Eur J Pharmacol 263:133-140.
82. Feng MG, Dukacz SA, and Kline RL (2001) Selective effect of tempol on renal medullary hemodynamics in spontaneously hypertensive rats. Am J Physiol 281:R1420-R1425.
83. Ferrario CM and Chappell MC (2004) Novel angiotensin peptides. Cell Mol Life Sci 61:2720-2727.
84. Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Smith RD, and Chappell MC (2005) Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 68:2189-2196.
85. For̈stermann U, Pollock JS, Schmidt HH, Heller M, and Murad F (1991) Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci USA 88:1788-1792.
86. Fortepiani LA, Ruiz MC, Passardi F, Bentley MD, Carcia-Estan J, Ritman EL, and Romero JC (2003) Effect of losartan on renal microvasculature during chronic inhibition of nitric oxide visualized by micro-CT. Am J Physiol 285: F852-F860.
87. Fujihara CK, De Nucci G, and Zatz R (1995) Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy. J Am Soc Nephrol 5:1498-1507.
88. Fujiki T, Shimokawa H, Morikawa K, Kubota H, Hatanaka M, Talukder MA, Matoba T, Takeshita A, and Sunagawa K (2005) Endothelium-derived hydrogen peroxide accounts for the enhancing effect of an angiotensin-converting enzyme inhibitor on endothelium-derived hyperpolarizing factor-mediated responses in mice. Arterioscler Thromb Vasc Biol 25:766-771.
89. Fukada SY, Tirapelli CR, de Godoy MA, and de Oliveira AM (2005) Mechanisms underlying the endothelium-independent relaxation induced by angiotensin II in rat aorta. J Cardiovasc Pharmacol 45:136-143.
90. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, and Sessa WC (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature (Lond) 399:597-601.
91. Furchgott RF (1988) Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide, in Vasodilatation: Vascular Smooth Muscle, Autonomic Nerves, and Endothelium (Vanhoutte PM ed) pp 401-414, Raven Press, Ltd., New York.
92. Furchgott RF, and Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine Nature (Lond) 288:373-376.
93. Gardes J, Poux JM, Gonzalez MF, Alhenc-Gelas F, and Menard J (1992) Decreased renin release and constant kallikrein secretion after injection of L-NAME in isolated perfused rat kidney. Life Sci 50:987-993.
94. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, and Mayer B (1995) Potential and selective inhibition of nitric oxide-sensitive guanylate cyclase by 1H[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-on. Mol Pharmacol 48:184-188.
95. Gauthier KM, Zhang DX, Edwards EM, Holmes B, and Campbell WB (2005) Angiotensin II dilates bovine adrenal cortical arterioles: role of endothelial nitric oxide. Endocrinology 146:3319-3324.
96. Gironacci MM, Valera MS, Yujnovsky I, and Pena C (2004a) Angiotensin-(1-7) inhibitory mechanism of norepinephrine release in hypertensive rats. Hypertension 44:783-787.
97. Gironacci MM, Yujnovsky I, Gorzalczany S, Taira C, and Pena C (2004b) Angiotensin-(1-7) inhibits the angiotensin II-enhanced norepinephrine release in coarcted hypertensive rats. Regul Pept 118:45-49.
98. Giugliano D, Marfella R, Acampora R, Giunta R, Coppola L, and D'Onofrio F (1998) Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care 21:631-636.
99. Goldstein I and Berman JR (1998) Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes. Int J Impot Res 10(Suppl 2):S84-S90.
100. Gomez-Alamillo C, Juncos LA, Cases A, Haas JA, and Romero JC (2003) Interactions between vasoconstrictors and vasodilators in regulating hemodynamics of distinct vascular beds. Hypertension 42:831-836.
101. Gorelik G, Carbini LA, and Scicli AG (1998) Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery. J Pharmacol Exp Ther 286:403-410.
102. Goto K, Fujii K, Kansui Y, and Iida M (2004) Changes in endothelium-derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with renin-angiotensin system inhibitors. Clin Exp Pharmacol Physiol 31:650-655.
103. Goto K, Fujii K, Onaka U, Abe I, and Fujishima M (2000a) Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension 36:575-580.
104. Goto K, Fujii K, Onaka U, Abe I, and Fujishima M (2000b) Angiotensin-converting enzyme inhibitor prevents age-related endothelial dysfunction. Hypertension 36:581-587.
105. Gryglewski RJ, Swies J, Uracz W, Chlopicki S, and Marcinkiewicz E (2003) Mechanisms of angiotensin-converting enzyme inhibitor induced thrombolysis in Wistar rats. Thromb Res 110:323-329.
106. Haefeli WE, Linder L, and Luscher TF (1997) Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans. Hypertension 30:912-917.
107. Hajj-ali AF and Zimmerman BG (1992) Nitric oxide participation in renal hemodynamic effect of angiotensin converting enzyme inhibitor lisinopril. Eur J Pharmacol 212:279-281.
108. +-ATPase activity via a NO/cGMP dependent pathway. Am J Physiol 290:F1430-F1436.
109. Hampl V, Archer SL, Nelson DP, and Weir EK (1993) Chronic EDRF inhibition and hypoxia: effects on pulmonary circulation and systemic blood pressure. J Appl Physiol 75:1748-1757.
110. 1 receptor-mediated contraction in rat uterine artery:involvement of bradykinin and nitric oxide. Br J Pharmacol 140:987-995.
111. Haque MZ and Majid DS (2004) Assessment of renal function phenotype in mice lacking gp91PHOX subunit of NAD(P)H oxidase. Hypertension 43:335-340.
112. Hardy P, Abran D, Hou X, Lahaie I, Peri KG, Asselin P, Varma DR, and Chemtob S (1998) A major role for prostacyclin in nitric oxide-induced ocular vasorelaxation in the piglet. Circ Res 83:721-729.
113. Haulica I, Bild W, and Serban DN (2005) Angiotensin peptides and their pleiotropic actions. J Renin Angiotensin Aldosterone Syst 6:121-131.
114. Hayashi K, Fujiwara K, Oka K, Nagahama T, Matsuda H, and Saruta T (1997) Effect of insulin on rat renal microvessel: studies in the isolated perfused hydronephrotic kidney. Kidney Int 51:1507-1513.
115. Heinemann A, Wachter CH, Peskar BA, and Holzer P (1997) Dilatation by angiotensin II of the rat femoral arterial bed in vivo via pressure/flow-induced release of nitric oxide and prostaglandins. Br J Pharmacol 122:975-984.
116. Heitzer T, Schlinzig T, Krohn K, Meinertz T, and Munzel T (2001) Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104:2673-2678.
117. Helmy A, Newby DE, Jalan R, Johnston NR, Hayes PC, and Webb DJ (2003) Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis. J Hepatol 38:44-50.
118. Hemmington BS, Zhang H, Miller MT, Granger JP, and Reckelhoff JF (1998) Angiotensin II stimulates synthesis of endothelial nitric oxide synthase. Hypertension 31:283-288.
119. Higashi Y, Oshima T, Sasaki S, Nakano Y, Kambe M, Matsuura H, and Kajiyama G (1998) Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to L-arginine in patients with essential hypertension. Hypertension 32:16-24.
120. Higashi Y, Sasaki S, Nakagawa K, Kimura M, Sasaki S, Noma K, Hara K, Matsuura H, Goto C, Oshima T, et al. (2002) Severity of hypertension affects improved resistance artery endothelial function by angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol 39:668-676.
121. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Kajiyama G, and Oshima T (2001) Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function. J Am Coll Cardiol 37:863-870.
122. Hill-Kapturczak N, Kapturczak MH, Block ER, Patel JM, Malinski T, Madsen KM, and Tisher CC (1999) Angiotensin II-stimulated nitric oxide release from porcine pulmonary endothelium is mediated by angiotensin IV. J Am Soc Nephrol 10:481-491.
123. 2 receptors in the pressure-overloaded aorta after banding. Hypertension 43:1258-1263.
124. 2 receptors in the pressure-overloaded aorta after banding. Hypertension 43:1258-1263.
125. Hiyoshi H, Yayama K, Takano M, and Okamoto H (2005) Angiotensin type 2 receptor-mediated phosphorylation of eNOS in the aortas of mice with 2-kidney, 1-clip hypertension. Hypertension 45:967-973.
126. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, Tatge H, and Drexler H (2001) Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 103:799-805.
127. Ichihara A, Inscho EW, Imig JD, and Navar LG (1998) Neuronal nitric oxide synthase modulates rat renal microvascular function. Am J Physiol 274:F516-F524.
128. 1 receptors regulate ACE2 and angiotensin-(1-7) expression in aorta of spontaneously hypertensive rats. Am J Physiol 289:H1013-H1019.
129. Ignarro LJ, Buga GM, Wood KS, Byrns RE, and Chaudhuri G (1987) Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84:9265-9269.
130. Ikenaga H, Fallet RW, and Carmines PK (1996) Basal nitric oxide production curtails arteriolar vasoconstrictor responses to ANG II in rat kidney. Am J Physiol 271:F365-F373.
131. Ito S, Carretero OA, and Abe K (1997) Role of nitric oxide in the control of glomerular microcirculation. Clin Exp Pharmacol Physiol 24:578-581.
132. Iyer SN, Yamada K, Diz DI, Ferrario CM, and Chappell MC (2000) Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system. J Cardiovasc Pharmacol 36:109-117.
133. Johnson RA and Freeman RH (1994) Renin release in rats during blockade of nitric oxide synthesis. Am J Physiol 266:R1723-R1729.
134. 1-receptor blockade after reperfused myocardial infarction. J Renin Angiotensin Aldosterone Syst 2:134-140.
135. Juncos LA, Ren Y, Arima S, Garvin J, Carretero OA, and Ito S (1996) Angiotensin II action in isolated microperfused rabbit afferent arterioles is modulated by flow. Kidney Int 49:374-381.
136. Kahonen M, Makynen H, Wu X, Arvola P, and Porsti I (1995) Endothelial function in spontaneously hypertensive rats: influence of quinapril treatment. Br J Pharmacol 115:859-867.
137. Kajihara N, Nishida T, Boku N, Tatewaki H, Eto M, and Morita S (2005) Angiotensin II type 1 receptor antagonist protects ventricular and coronary endothelial function after 24-hour heart preservation. J Heart Lung Transplant 24:221 1-2217.
138. 1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 40:521-527.
139. Kansui Y, Fujii K, Nakamura K, Goto K, Onishi H, Abe I, Shibata Y, and Iida M (2004) Angiotensin II receptor blockade corrects altered expression of gap junctions in vascular endothelial cells from hypertensive rats. Am J Physiol 287:H216-H224.
140. Kawazoe T, Kosaka H, Yoneyama H, and Hata (1999) Involvement of superoxide in acute reaction of angiotensin II in mesenteric microcirculation. Jpn J Physiol 49:437-443.
141. Kazama K, Anrather J, Zhou P, Girouard H, Frys K, Milner TA, and Iadecola C (2004) Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res 95:1019-1026.
142. Kichuk MR, Zhang X, Oz M, Michler R, Kaley G, Nasjletti A, and Hintze TH (1997) Angiotensin-converting enzyme inhibitors promote nitric oxide production in coronary microvessels from failing explanted human hearts. Am J Cardiol 80:137A-142A.
143. Kihara M, Mitsui MK, Mistui Y, Okuda K, Nakasaka Y, Takahashi M, and Schmelzer JD (1999) Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of nitric oxide. Muscle Nerve 22:920-925.
144. Kihara M, Sato K, Hashimoto T, Imai N, Toya Y, and Umemura S (2005) Expression of endothelial nitric oxide synthase is suppressed in the renal vasculature of angiotensinogen-gene knockout mice. Cell Tissue Res 28:1-8.
145. Kinugawa S, Post H, Kaminski PM, Zhang X, Xu X, Huang H, Recchia FA, Ochoa M, Wolin MS, Kaley G, et al. (2003) Coronary microvascular endothelial stunning after acute pressure overload in the conscious dog is caused by oxidant processes: the role of angiotensin II type 1 receptor and NAD(P)H oxidase. Circulation 108:2934-2940.
146. Kitakaze M, Asanuma H, Funaya H, Node K, Takashima S, Sanada S, Asakura M, Ogita H, Kim J, and Hori M (2002) Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium: role of bradykinin. J Am Coll Cardiol 40:162-166.
147. Kitakaze M, Minamino T, Node K, Komamura K, Shinozaki Y, Mori H, Kosaka H, Inoue M, Hori M, and Kamada T (1995) Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation 92:950-961.
148. Kitakaze M, Node K, Minamino T, Asanuma H, Ueda Y, Kosaka H, Kuzuya T, and Hori M (1998) Inhibition of angiotensin-converting enzyme increases the nitric oxide levels in canine ischemic myocardium. J Mol Cell Cardiol 30:2461-2466.
149. K-Laflamme A, Oster L, Cardinal R, and de Champlain J (1998) Role of NO
150. 1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 16:123-128.
151. Kohagura K, Endo Y, Ito O, Arima S, Omata K, and Ito S (2000) Endogenous nitric oxide and epoxyeicosatrienoic acids modulate angiotensin II-induced constriction in the rabbit afferent arteriole. Acta Physiol Scand 168:107-112.
152. Komers R, Oyama TT, Chapman JG, Allison KM, and Anderson S (2000) Effects of systemic inhibition of neuronal nitric oxide synthase in diabetic rats. Hypertension 35:655-661.
153. Kramar EA, Krishnan R, Harding JW, and Wright JW (1998) Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow. Regul Pept 74:185-192.
154. Kramer HJ, Horacek V, Backer A, Vaneckova I, and Heller J (2004) Relative roles of nitric oxide, prostanoids and angiotensin II in the regulation of canine glomerular hemodynamics: a micropuncture study. Kidney Blood Press Res 27:10-17.
155. Kulkarni P, Cai J, and Hurst HE (2002) Lipids and nitric oxide in porcine retinal and choroidal blood vessels. J Ocul Pharmacol 18:265-275.
156. Kumar KV and Das UN (1993) Are free radicals involved in the pathobiology of human essential hypertension? Free Radic Res Commun 19:59-66.
157. Kurisu S, Ozono R, Oshima T, Kambe M, Ishida T, Sugino H, Matsuura H, Chayama K, Teranshi Y, Iba O, et al. (2003) Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 41:99-107.
158. Lambers DS, Greenberg SG, and Clark KE (2000) Functional role of angiotensin II type 1 and 2 receptors in regulation of uterine blood flow in nonpregnant sheep. Am J Physiol 278:H353-H359.
159. Lansang MC and Hollenberg NK (2002) Renal perfusion and the renal hemodynamic response to blocking the renin system in diabetes: are the forces leading to vasodilation and vasoconstriction linked? Diabetes 51:2025-2028.
160. Lee BH and Shin HS (1997) Interaction of nitric oxide and the renin angiotensin system in renal hypertensive rats. Jpn J Pharmacol 74:83-90.
161. Lemos VS, Silva DM, Walther T, Alenina N, Bader M, and Santos RA (2005) The endothelium-dependent vasodilator4 effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of Mas-knockout mice. J Cardiovasc Pharmacol 46:274-279.
162. Lerman LO, Nath KA, Rodriguez-Porcel M, Krier JD, Schwartz RS, Napoli C, and Romero JC (2001) Increased oxidative stress in experimental renovascular hypertension. Hypertension 37:541-546.
163. Li B, Yao J, Kawamura K, Oyanagi-Tanaka Y, Hoshiyama M, Morioka T, Gejyo F, Uchiyama M, and Oite T (2004) Real-time observation of glomerular hemodynamic changes in diabetic rats: effects of insulin and ARB. Kidney Int 66:1939-1948.
164. Li P, Chapel MC, Ferrario CM, and Brosnihan KB (1997) Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 29:394-400.
165. Li Q, Zhang L, Pfaffendorf M, and van Zwieten PA (1995) Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta. Br J Pharmacol 116:2963-2970.
166. Linz W, Itter G, Dobrucki LW, Malinski T, and Wiemer G (2003) Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction. J Renin Angiotensin Aldosterone Syst 4:180-185.
167. Llinas MT, Gonzalez JD, Nava E, and Salazar FJ (1997) Role of angiotensin II in the renal effects induced by nitric oxide and prostaglandin synthesis inhibition. J Am Soc Nephrol 8:543-550.
168. Llinas MT, Gonzalez JD, and Salazar FJ (1995) Interactions between angiotensin and nitric oxide in the renal response to volume expansion. Am J Physiol 269:R504-R510.
169. Lum C, Shesely EG, Potter DL, and Beierwaltes WH (2004) Cardiovascular and renal phenotype in mice with one or two renin genes. Hypertension 43:79-86.
170. Machado RD, Ferreira MA, Belo AV, Santos RA, and Andrade SP (2002) Vasodilator effect of angiotensin-(1-7) in mature and sponge-induced neovasculature. Regul Pept 107:105-113.
171. Machado RD, Santos RA, and Andrade SP (2001) Mechanisms of angiotensin-(1-7)-induced inhibition of angiogenesis. Am J Physiol 280:R994-R1000.
172. Madrid MI, Garcia-Salom M, Tornel J, De Gasparo M, and Fenoy FJ (1997a) Effect of interactions between nitric oxide and angiotensin II on pressure diuresis and natriuresis. Am J Physiol 273:R1676-R1682.
173. Madrid MI, Garcia-Salom M, Tornel J, de Gasparo M, and Fenoy FJ (1997b) Interactions between nitric oxide and angiotensin II on renal cortical and papillary blood flow. Hypertension 30:1175-1182.
174. Maeso R, Rodrigo E, Munoz-Garcia R, Navarro-Cid J, Ruilope LM, Cachofeiro V, and Lahera V (1998) Factors involved in the effects of losartan on endothelial dysfunction induced by aging in SHR. Kidney Int Suppl 68:S30-S35.
175. Martens FM, Visseren FL, de Koning EJ, and Rabelink TJ (2005) Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 46:773-778.
176. Martinez Y, Martinez S, Meaney A, Meaney E, and Escalante B (2002) Angiotensin II type 1 receptor blockade restores nitric oxide-dependent renal vascular responses in renovascular hypertension. J Cardiovasc Pharmacol 40:381-387.
177. Matsuda H, Hayashi K, Arakawa K, Naitoh M, Kubota E, Honda M, Matsumoto A, Suzuki H, Yamamoto T, Kajiya F, et al. (1999) Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin. J Am Soc Nephrol 10:2272-2282.
178. Matsuda H, Hayashi K, Wakino S, Kubota E, Honda M, Tokuyama H, Takamatsu I, Tatematsu S, and Saruta T (2004) Role of endothelium-derived hyperpolarizing factor in ACE inhibitor-induced renal vasodilation in vivo. Hypertension 43:603-609.
179. Mattson DL and Meister CJ (2005) Renal cortical and medullary blood flow responses to L-NAME and ANG II in wild-type, nNOS null mutant, and eNOS null mutant mice. Am J Physiol 289:R991-R997.
180. Maveri L, Stromberg C, and Saavedra JM (1994) Angiotensin IV reverses the acute cerebral blood flow reduction after experimental subarachnoid hemorrhage in the rat. J Cereb Blood Flow Metab 14:1096-1099.
181. McLay JS, Chatterjee PK, Mistry SK, Weerakody RP, Jardine AG, McKay NG, and Hawksworth GM (1995) Atrial natriuretic factor and angiotensin II stimulate nitric oxide release from human proximal tubular cells. Clin Sci (Lond) 89:527-531.
182. Meyer P, Flammer J, and Luscher TF (1995) Local action of the renin angiotensin system in the porcine ophthalmic circulation: effects of ACE-inhibitors and angiotensin receptor antagonists. Investig Ophthalmol Vis Sci 36:555-562.
183. 2+-calmodulin and caveolin. J Biol Chem 272:15583-15586.
184. Mimran A, Ribstein J, and DuCailar G (1995) Contrasting effect of Antihypertensive treatment on the renal response to L-arginine. Hypertension 26:937-941.
185. Minami Y and Toda N (1988) Comparison of the response to angiotensin II of isolated dog coronary and mesenteric arteries of proximal and distal portions. Arch Int Pharmacodyn Ther 293:186-195.
186. Mitsube K, Mikuni M, Matousek M, Zackrisson U, and Brannstrom M (2003) Role of the angiotensin II system in regulation of ovulation and blood flow in the rat ovary. Reproduction 125:425-435.
187. Mohazzab KM, Kaminski PM, and Wolin MS (1994) NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 266:H2568-H2572.
188. Mohri M, Tagawa H, Egashira K, and Tekeshita A (2000) Intracoronary enalaprilat improves metabolic coronary vasodilation in patients with idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 35:249-255.
189. Mombouli JV, Nakashima M, Hamra M, and Vanhoutte PM (1996) Endothelium-dependent relaxation and hyperpolarization evoked by bradykinin in canine coronary arteries: enhancement by exercise-training. Br J Pharmacol 117:413-418.
190. Moncada S, Gryglewski R, Bunting S, and Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (Lond) 263:663-665.
191. Moore PK, Babbedge RC, Wallace P, Gaffen ZA, and Hart SL (1993) 7-Nitroindazole, an inhibitor of nitric oxide synthase, exhibits anti-nociceptive activity in the mouse without increasing blood pressure. Br J Pharmacol 108:296-297.
192. Mori T, Cowley AW, and Ito S (2006) Molecular mechanisms and therapeutic strategies of chronic renal injury: physiological role of angiotensin II-induced oxidative stress in renal medulla. J Pharmacol Sci 100:2-8.
193. Nabah YN, Mateo T, Cerda-Nicolas M, Alvarez A, Marinez M, Issekuta AC, and Sanz MJ (2005) L-NAME induces direct arteriolar leukocyte adhesion, which is mainly mediated by angiotensin-II. Microcirculation 12:443-453.
194. Naess PA, Christensen G, Kirkeboen KA, and Kiil F (1993) Effect on renin release of inhibiting renal nitric oxide synthesis in anaesthetized dog. Acta Physiol Scand 148:137-142.
195. Najafipour H and Ketabchi F (2003) The receptors and role of angiotensin II in knee point blood flow regulation and role of nitric oxide in modulation of their function. Microcirculation 10:383-390.
196. Nakae I, Takahashi M, Kinoshita T, Matsumoto T, and Kinoshita M (1995) The effect of S-nitrosocaptopril on canine coronary circulation. J Pharmacol Exp Ther 274:40-46.
197. Navar LG, Ichihara A, Chin SY, and Imig JD (2000) Nitric oxide-angiotensin interactions in angiotensin II-dependent hypertension. Acta Physiol Scand 168:139-147.
198. Naveri L (1995) The role of angiotensin receptor subtypes in cerebrovascular regulation in the rat. Acta Physiol Scand Suppl 630:1-48.
199. Neri Serneri GG, Boddi M, Modesti PA, Coppo M, Cecioni I, Toscano T, Papa ML, Bandinelli M, Lisi GF, and Chiavarelli M (2004) Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Circ Res 94:1630-1632.
200. Nickenig G, Stablein A, Wassmann S, Wyen C, Muller C, and Bohm M (2000) Acute effects of ACE inhibition on coronary endothelial dysfunction. J Renin Angiotensin Aldosterone Syst 1:361-364.
201. Nielsen S, Halliwill JR, Joyner MJ, and Jensen MD (2004) Vascular response to angiotensin II in upper body obesity. Hypertension 44:435-441.
202. Nikolaidis LA, Doverspike A, Huerbin R, Hentosz T, and Shannon RP (2002) Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism. Circulation 105:2785-2790.
203. Nishiyama A, Fujisawa Y, Fukui T, Rahman M, Kondo N, Ogawa Y, Fanzhu L, Guoxing Z, Kimura S, and Abe Y (2001) Role of nitric oxide in regional blood flow in angiotensin II-induced hypertensive rats. Hypertens Res 24:421-427.
204. 2 signal and NO pathways. Circ Res 93:523-530.
205. Nossaman BD, Feng CJ, Kaye AD, and Kadowitz PJ (1995) Analysis of responses to ANG IV: effects of PD-123319 and Dup-753 in the pulmonary circulation of the rat. Am J Physiol 268:L302-L308.
206. Novak J, Reckelhoff J, Bumgarner L, Cockrell K, Kassab S, and Granger JP (1997) Reduced sensitivity of the renal circulation to angiotensin II in pregnant rats. Hypertension 30:580-584.
207. Nowicki PT (1999) Effects of sustained low-flow perfusion on the response to vasoconstrictor agents in postnatal intestine. Am J Physiol 276:G1408-G1416.
208. 2 receptor-deficient mice after DOCA-salt. Kidney Int 65:2268-2278.
209. Ohishi K, Carmines PK, Inscho EW, and Navar LG (1992) EDRF-angiotensin II interactions in rat juxtamedullary afferent and efferent arterioles. Am J Physiol 263:F900-F906.
210. Oka M, Ohnishi M, Takahashi H, Soma S, Hasunuma K, Sato K, and Kira S (1996) Altered vasoreactivity in lungs isolated from rats exposed to nitric oxide gas. Am J Physiol 271:L419-L424.
211. Oliver JJ, Rajapakse NW, and Evans RG (2002) Effects of indomethacin on responses of regional kidney perfusion to vasoactive agents in rabbits. Clin Exp Pharmacol Physiol 29:873-879.
212. Ollerstam A, Salomonsson M, and Persson AE (2002) Reduced rat renal vascular response to angiotensin II after chronic inhibition of nNOS. Acta Physiol Scand 176:245-252.
213. Olson S, Oeckler R, Li X, Du L, Traganos F, Zhao X, and Burke-Wolin T (2004) Angiotensin II stimulates nitric oxide production in pulmonary artery endothelium via the type 2 receptor. Am J Physiol 287:L559-L568.
214. On YK, Kim CH, Oh BH, Lee MM, and Park YB (2002) Effects of angiotensin converting enzyme inhibitor and calcium antagonist on endothelial function in patients with essential hypertension. Hypertens Res 25:365-371.
215. Onaka U, Fhjii K, Abe I, and Fujishima M (1998) Antihypertensive treatment improves endothelium-dependent hyperpolarization in the mesenteric artery of spontaneously hypertensive rats. Circulation 98:175-182.
216. Ono H, Ono Y, Takanohashi A, Matsuoka H, and Frohlich ED (2001) Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in spontaneously hypertensive rats. Hypertension 38:1300-1306.
217. Ono N, Acachi Y, Hashimoto K, Yoshida M, Suzuki-Kusaba M, Hisa H, and Satoh S (1998) A nitric oxide donor NOC 7 suppresses renal responses induced by norepinephrine and angiotensin II in the NO-depleted denervated rabbit kidney. Eur J Pharmacol 342:285-289.
218. 1 receptors in the renal papillary effects of acute and chronic nitric oxide inhibition. Am J Physiol 274:R760-R766.
219. Osei SY, Ahima RS, Minkes RK, Weaver JP, Khosla MC, and Kadowitz PJ (1993) Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol 234:35-42.
220. Ozawa Y, Hayashi K, Wakino S, Kanda T, Homma K, Takamatsu I, Tatematsu S, Yoshioka K, and Saruta T (2004) Free radical activity depends on underlying vasoconstrictors in renal microcirculation. Clin Exp Hypertens 26:219-229.
221. Paliege A, Parsumathy A, Mizel D, Yang T, Schnermann J, and Bachmann S (2006) Effect of apocynin treatment on renal expression of COX-2, NOS1, and rennin in Wistar-Kyoto and spontaneously hypertensive rats. Am J Physiol 290:R694-R700.
222. Palmer RM, Ferrige AG, and Moncada S (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (Lond) 327:524-526.
223. Palmer RM, Rees DD, Ashton DS, and Moncada S (1988) L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 153:1251-1256.
224. Parekh N, Dobrowolski L, Zou AP, and Steinhausen M (1996) Nitric oxide modulates angiotensin II- and norepinephrine-dependent vasoconstriction in rat kidney. Am J Physiol 270:R630-R635.
225. Park JK, Kim SZ, Kim JU, Kim YG, Kim SM, and Cho KW (2002) Comparison of effects of angiotensin peptides in the regulation of clitoral cavernosum smooth muscle tone. Int J Impot Res 14:72-80.
226. Park JK, Kim SZ, Kim SH, Kim YG, and Cho KW (2000) Renin angiotensin system of rabbit clitoral cavernosum: interaction with nitric oxide. J Urol 164:556-561.
227. Patel JM, Li YD, Zhang J, Gelband CH, Raizada MK, and Block ER (1999) Increased expression of calreticulin is linked to ANG IV-mediated activation of lung endothelial NOS. Am J Physiol 277:L794-L801.
228. Patel JM, Martens JR, Li YD, Gelband CH, Raizada MK, and Block ER (1998) Angiotensin IV receptor-mediated activation of lung endothelial NOS I associated with vasorelaxation. Am J Physiol 275:L1061-L1068.
229. 1 receptors mediate angiotensin II-induced release of nitric oxide in afferent arterioles. Kidney Int 66:1949-1958.
230. Persdson PB, Baumann JE, Ehmke H, Hackenthal E, Kirchheim HR, and Nafz B (1993) Endothelium-derived NO stimulates pressure-dependent renin release in conscious dogs. Am J Physiol 264:F943-F947.
231. Pieber D, Horina G, Sandner-Kiesling A, Piber TR, and Heinemann A (1999) Pressor and mesenteric arterial hyporesponsiveness to angiotensin II is an early event in haemorrhagic hypotension in anaesthetized rats. Cardiovasc Res 44:166-175.
232. Pinheiro SV, Simoes e Silva AS, Sampaio WO, de Paula RD, Mendes EP, Bontempo ED, Persquero JB, Walther T, Alenina N, Bader M, et al. (2004) Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 44:490-496.
233. Polikandriotis JA, Mazzella LJ, Rupnow HL, and Hart CM (2005) Peroxisome proliferator-activated receptor-γ ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor-γ-dependent mechanisms. Arterioscler Thromb Vasc Biol 25:1810-1816.
234. Porsti I, Bara AT, Busse R, and Hecker M (1996) Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol 111:652-654.
235. Porsti I, Hecker M, Bassenge E, and Busse R (1993) Dual action of angiotensin II on coronary resistance in the isolated perfused rabbit heart. Naunyn-Schmiedeberg's Arch Pharmacol 348:650-658.
236. Prasad A, Husain S, and Quyyumi AA (1999) Effect of enalaprilat on nitric oxide activity in coronary artery disease. Am J Cardiol 84:1-6.
237. 1-adrenergic tone in chronic nitric oxide blockade-induced hypertension. Am J Physiol 266:R1470-R1476.
238. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, and Griendling KK (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Investig 97:1916-1923.
239. Rajapakse NW, Sampson AK, Eppel GA, and Evans RG (2005) Angiotensin II and nitric oxide in neural control of intrarenal flood flow. Am J Physiol 289:R745-R754.
240. Resende AC, Pimentel AM, and de Moura RS (2004) Captopril reverses the reduced vasodilator response to bradykinin in hypertensive pregnant rats. Clin Exp Pharmacol Physiol 31:756-761.
241. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, and Zatz R (1992) Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension 20:298-303.
242. 2 receptor activation regulates myocardial eNOS expression via the calcineurin-NF-AT pathway. FASEB J 17:283-285.
243. Roccatello D, Mengozzi G, Gigliola G, Rossi D, Mosso R, Cacace G, Polloni R, Cesano G, Picciotto G, Paradisi L, et al. (2000) Effects of angiotensin II blockade on nitric oxide blood levels in IgA nephropathy. Nephrol Dial Transplant 15:988-993.
244. Rodriquez A, Martin A, Oterino JA, Blanco I, Jimenez M, Perez A, and Novoa JM (1999) Renal function in compensated hepatic cirrhosis: effects of an amino acid infusion and relationship with nitric acid. Dig Dis 17:235-240.
245. Roks AJ, Nijholt J, van Buiten A, Gilst WH, de Zeeuw D, and Henning RH (2004) Low sodium diet inhibits the local counter-regulator effect of angiotensin-(1-7) on angiotensin II. J Hypertens 22:2355-2361.
246. Rosenkranz AC, Hood SG, Woods RL, Dusting GJ, and Ritchie RH (2002) Acute antihypertrophic actions of bradykinin in the rat heart: importance of cyclic GMP. Hypertension 40:498-503.
247. Rowe BP and Dixon B (2000) Angiotensin III depressor action in the conscious rabbit is blocked by losartan but not PD 123319. Hypertension 35:130-134.
248. Rudenstam J, Creutz J, Gothberg G, Karlstrom G, and Bergstrom G (2000) Regional renal haemodynamics of angiotensin II infusion under prostaglandin, kinin or converting enzyme inhibition in the Wistar4 rat. Blood Press 9:169-175.
249. Rugale C, Cordaillat M, Mimuran A, and Jover B (2005) Prevention and reversal by enalapril of target organ damage in angiotensin II hypertension. J Renin Angiotensin Aldosterone Syst 6:154-160.
250. Saha PR, Alsip NL, Henzel MK, and Asher EF (1998) Role of nitric oxide and cyclooxygenase products in controlling vascular tone in uterine microvessels of rats. J Reprod Fertil 112:211-216.
251. 1 receptors. Hypertens Res 19:201-206.
252. Sanchez-Mendoza A, Hong E, and Escalante B (1998) The role of nitric oxide in angiotensin II-induced renal vasoconstriction in renovascular hypertension. J Hypertens 16:697-703.
253. Santos RA, Simoes e Silva AC, Maric C, Sila DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100:8258-8263.
254. Sarkis A, Liu KL, Lo M, and Benzoni D (2003) Angiotensin II and renal medullary blood flow in Lyon rats. Am J Physiol 284:F365-F372.
255. Sasaki S, Higashi Y, Nakagawa K, Matsuura H, Kajiyama G, and Oshima T (2001) Effects of angiotensin-(1-7) on forearm circulation in normotensive subjects and patients with essential hypertension. Hypertension 38:90-94.
256. Sasaki Y, Noguchi T, Seki J, Giddings JC, and Yamamoto J (2000) Protective effects of imidapril on He-Ne laser-induced thrombosis in cerebral blood vessels of stroke-prone spontaneously hypertensive rats. Thromb Haemost 83:722-727.
257. Sato H, Yaoita H, Maehara K, and Maruyama Y (2003) Attenuation of heart failure due to coronary stenosis by ACE inhibitor and angiotensin receptor blocker. Am J Physiol 285:H359-H368.
258. Schnackenberg C, Tucker B, Pigg K, and Granger J (1997) Role of nitric oxide in modulating the chronic renal and arterial pressure responses to angiotensin II. Am J Hypertens 10:226-229.
259. Schnackenberg CG, Wilkins FC, and Granger JP (1995) Role of nitric oxide in modulating the vasoconstrictor actions of angiotensin II in preglomerular and postglomerular vessels in dogs. Hypertension 26:1024-1029.
260. Scholz H and Kurtz A (1993) Involvement of endothelium-derived relaxing factor in the pressure control of renin secretion from isolated perfused kidney. J Clin Investig 91:1088-1094.
261. Schoonmaker GC, Fallet RW, and Carmines PK (2000) Superoxide anion curbs nitric oxide modulation of afferent arteriolar ANG II responsiveness in diabetes mellitus. Am J Physiol 278:F302-F309.
262. Schricker K, Della Bruna R, Hamann M, and Kurtz A (1994) Endothelium derived relaxing factor is involved in the pressure control of renin gene expression in the kidney. Pflueg Arch Eur J Physiol 428:261-268.
263. Schricker K, Hegyi I, Hamann M, Kaissling B, and Kurtz A (1995) Tonic stimulation of renin gene expression by nitric oxide is counteracted by tonic inhibition through angiotensin II. Proc Natl Acad Sci USA 92:8006-8010.
264. Schricker K and Kurtz A (1993) Liberators of NO exert a dual effect on renin secretion from isolated mouse renal juxtaglomerular cells. Am J Physiol 265:F180-F186.
265. Schupp M, Janke J, Clasen R, Unger T, and Kintscher U (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109:2054-2057.
266. Seyedi N, Xu X, Nasjletti A, and Hintze TH (1995) Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 26:164-170.
267. 2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood 108:192-199.
268. Sigmon DH and Beierwaltes WH (1993a) Angiotensin II: nitric oxide interaction and the distribution of blood flow. Am J Physiol 265:R1276-R1283.
269. Sigmon DH and Beierwaltes WH (1993b) Renal nitric oxide and angiotensin II interaction in renovascular hypertension. Hypertension 22:237-242.
270. Sigmon DH and Beierwaltes WH (1998) Influence of nitric oxide in the chronic phase of two-kidney, on clip renovascular hypertension. Hypertension 31:649-656.
271. Sigmon DH, Carretero OA, and Beierwaltes WH (1992) Angiotensin dependence of endothelium-mediated renal hemodynamics. Hypertension 20:643-650.
272. Sigmon DH, Carretero OA, and Beierwaltes WH (1992) Endothelium-derived relaxing factor regulates renin release in vivo. Am J Physiol 263:F256-F261.
273. Sigmon DH, Carretero OA, and Beierwaltes WH (1993) Renal versus femoral hemodynamic response to endothelium-derived relaxing factor synthesis inhibition. J Vasc Res 30:218-223.
274. Sigmon DH, Newman JM, and Beierwaltes WH (1994) Angiotensin II: endothelium-derived nitric oxide interaction in conscious rats. J Am Soc Nephrol 4:1675-1682.
275. Sim JS, Farquharson C, and Struthers AD (2004) Tonic levels of angiotensin II reduce tonic levels of vascular nitric oxide even in salt-replete man. J Renin Angiotensin Aldosterone Syst 5:84-88.
276. 2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Investig 100:264-269.
277. 2 receptor in a renal wrap hypertension model. Hypertension 33:1237-1242.
278. 2) angiotensin receptor. Proc Natl Acad Sci USA 96:6506-6510.
279. Solhaug MJ, Ballevre LD, Guignard JP, Granger JP, and Adelman RD (1996a) Nitric oxide in the developing kidney. Pediatr Nephrol 10:529-539.
280. Solhaug MJ, Wallace MR, and Granger JP (1996b) Nitric oxide and angiotensin II regulation of renal hemodynamics in the developing piglet. Pediatr Res 39:527-533.
281. 2 receptor-mediated hypotension. J Hum Hypertens 14(Suppl 1):S40-S46.
282. Springate J, Van Liew J, and Ganten D (1997) Enalapril and pressure-diuresis in hypertensive rats transgenic for mouse renin gene. Kidney Blood Press Res 20:1-5.
283. 1 receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs: comparison with B2 receptor stimulation. Circulation 101:1848-1853.
284. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, Tsujimoto T, Toyohira Y, Hayashida Y, Sasaguri Y, et al. (2004) Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 24:1682-1688.
285. Sudhir K, MacGregor JS, Gupta M, Barbant SD, Redberg R, Yock PG, and Chatterjee K (1993) Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo: intravascular two-dimensional and Doppler ultrasound studies. Circulation 87:931-938.
286. Symons JD, Musch TI, Hageman KS, and Stebins CL (1999a) Regional blood flow responses to acute ANG II infusion: effects of nitric oxide synthase inhibition. J Cardiovasc Pharmacol 34:116-123.
287. Symons JD, Stebbins CL, and Musch TI (1999b) Interactions between angiotensin II and nitric oxide during exercise in normal and heart failure rats. J Appl Physiol 87:574-581.
288. Szentivanyi M Jr, Maeda CY, and Cowley AW Jr (1999) Local renal medullary L-NAME infusion enhances the effect of long-term angiotensin II treatment. Hypertension 33:440-445.
289. Szentivanyi M Jr, Zou AP, Mattson DL, Soares P, Moreno C, Roman RJ, and Cowley AW Jr (2002) Renal medullary nitric oxide deficit of Dahl S rats enhances hypertensive actions of angiotensin II. Am J Physiol 283:R266-R272.
290. + channels, inhibits coronary vasodilation induced by angiotensin II-receptor antagonist. J Cardiovasc Pharmacol 30:313-319.
291. Takai S, Kirimura K, Jin D, Muramatsu M, Yoshikawa K, Mino Y, and Miyazaki M (2005) Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 28:593-600.
292. Takeda K, Fujita H, Nakamura K, Uchida A, Tanaka M, Ito H, Nakata T, Sasaki S, and Nakagawa M (1994) Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats. Blood Press Suppl 5:94-98.
293. Takenaka T, Mitchell KD, and Navar LG (1993) Contribution of angiotensin II to renal hemodynamic and excretory responses to nitric oxide synthesis inhibition in the rat. J Am Soc Nephrol 4:1046-1053.
294. Tallant EA and Clark MA (2003) Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 42:574-579.
295. Talukder MA, Fujiki T, Morikawa K, Motoishi M, Matsuo Y, Hatanaka M, Tsutui M, Takeshita A, and Shimokawa H (2004) Endothelial nitric oxide synthase-independent effects of an ACE inhibitor on coronary flow response to bradykinin in aged mice. J Cardiovasc Pharmacol 44:557-563.
296. 2 receptor. J Pharmacol Exp Ther 307:1171-1178.
297. Tharaux PL, Dussaule JC, Pauti MD, Vassitch Y, Ardaillou R, and Chatziantoniou C (1997) Activation of renin synthesis is dependent on intact nitric oxide production. Kidney Int 51:1780-1787.
298. Toblli JE, Cao G, DeRosa G, Di Gennaro F, and Forcada P (2004) Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats. Am J Hypertens 17:172-180.
299. Toda N, Ayajiki K, and Okamura T (1990) Modifications by endogenous prostaglandins of angiotensin II-induced contractions in dog and monkey cerebral and mesenteric arteries. J Pharmacol Exp Ther 252:374-379.
300. Trauernicht AK, Sun H, Patel KP, and Mayhan WG (2003) Enalapril prevents impaired nitric oxide synthase-dependent dilatation of cerebral arterioles in diabetic rats. Stroke 34:2698-2703.
301. Triggle CR and Ding H (2002) Endothelium-derived hyperpolarizing factor: is there a novel chemical mediator? Clin Exp Pharmacol Physiol 29:153-160.
302. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, et al. (1999) Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Investig 104:925-935.
303. Turkstra E, Braam B, and Koomans HA (1998a) Losartan attenuates modest but not strong renal vasoconstriction induced by nitric oxide inhibition. J Cardiovasc Pharmacol 32:593-600.
304. Turkstra E, Braam B, and Koomans HA (1998b) Nitric oxide release as an essential mitigating step in tubuloglomerular feedback: observations during intrarenal nitric oxide clamp. J Am Soc Nephrol 9:1596-1603.
305. Urabe K, Matsumura Y, Nonaka H, Nishiura M, Maeda K, and Morimoto S (1996) Role of endogenous angiotensin II in renal hemodynamic and excretory responses to l-arginine infusion. Biol Pharm Bull 19:1149-1153.
306. 1) receptor blockade enhances the L-NAME-induced vasoconstriction in rat submandibular gland. Exp Physiol 87:327-333.
307. Vallance P, Leone A, Calver A, Collier J, and Moncada S (1992) Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 20(Suppl 12):S60-S62.
308. +-ATPase activity on unilateral ureteral obstruction: interaction of endogenous nitric oxide and angiotensin II. Kidney Int 58:1641-1651.
309. van der Linde NA, van den Meiracker AH, and Boomsma F (2003) Role of angiotensin II in L-NAME-induced systemic and renal hemodynamic effects in hydrochlorothiazide-pretreated hypertensive subjects. J Hypertens 21:345-351.
310. van Gilst WH, de Graeff PA, de Leeuw MJ, Scholtens E, and Wesseling H (1991) Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilators. J Cardiovasc Pharmacol 18:429-436.
311. Vaneckova I, Kramer HJ, Maly J, Backer A, Bokemeyer D, and Cervenka L (2002) Lack of a role of neuronal nitric oxide synthase in the regulation of the renal function in rats fed a low-sodium diet. Kidney Blood Press Res 25:224-231.
312. Vedrinne C, Tronc F, Martinot S, Robin J, Allevard AM, Vincent M, Lehot JJ, Franck M, and Champsaur C (2000) Better preservation of endothelial function and decreased activation of the fetal renin-angiotensin pathway with the use of pulsatile flow during experimental fetal bypass. J Thorac Cardiovasc Surg 120:770-777.
313. Wackenfors A, Vikman P, Nilsson E, Edvinsson L, and Malmsjo M (2006) Angiotensin II-induced vasodilatation in cerebral arteries is mediated by endothelium-derived hyperpolarizing factor. Eur J Pharmacol 531:259-263.
314. - and endothelium. J Vasc Res 43:109-119.
315. Warren JB and Loi RK (1995) Captopril increases skin microvascular blood flow secondary to bradykinin, nitric oxide, and prostaglandins. FASEB J 9:411-418.
316. 2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci USA 74:3922-3926.
317. Westendorp B, Schoeaker RG, van Gilst WH, and Buikema H (2005) Improvement of EDHF by chronic ACE inhibition declines rapidly after withdrawal in rats with myocardial infarction. J Cardiovasc Pharmacol 46:766-772.
318. Wickman A, Andersson IJ, Jia J, Hedin L, and Bergstrom G (2001) Endothelial nitric oxide synthase protein is reduced in the renal medulla of two-kidney, on-clip hypertensive rats. J Hypertens 19:1665-1673.
319. Wiemer G, Dobrucki LW, Louka FR, Malinski T, and Heitsch H (2002) AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 40:847-852.
320. Wiemer G, Popp R, Scholkens BA, and Gogelein H (1994) Enhancement of cytosolic calcium, prostacyclin and nitric oxide by bradykinin and the ACE inhibitor ramiprilat in porcine brain capillary endothelial cells. Brain Res 638:261-266.
321. Wienen W, Entzeroth M, van Meel JC, Stangier J, Busch U, Ebner T, Schmid J, Lehmann H, Matzek K, Kempthorne-Rawson J, et al. (2000) A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 18:127-156.
322. Wierema TK, Houben AJ, Kroon AA, Koster D, van der Zander K, van Engelshoven JM, and de Leeuw PW (2001) Nitric oxide dependence of renal blood flow in patients with renal artery stenosis. J Am Soc Nephrol 12:1836-1843.
323. Wilson SK (1990) Role of oxygen-derived free radicals in acute angiotensin II-induced hypertensive vascular disease in the rat. Circ Res 66:722-734.
324. Wolf G (2000) Free radical production and angiotensin. Curr Hypertens Rep 2:167-173.
325. Wolf G, Wenzel U, Hannken T, and Stahl RA (2001) Angiotensin II induces p27(Kip1) expression in renal tubules in vivo: role of reactive oxygen species. J Mol Med 79:382-389.
326. 1 receptor inhibition. J Cereb Blood Flow Metab 23:371-380.
327. Yang YY, Lin HC, Huang YT, Lee TY, Hou MC, Lee FY, Liu RS, Chang FY, and Lee SD (2002) Effect of 1-week losartan administration on bile duct-ligated cirrhotic rats. J Hepatol 36:600-606.
328. Yayama K, Wang C, Chao L, and Chao J (1998) Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 31:1104-1110.
329. Yoshida M, Kikukawa M, Hisa H, and Satoh S (1996) Modulation by nitric oxide and prostaglandins of the renal vascular response to angiotensin II (3-8). Br J Pharmacol 117:885-890.
330. Yu ZY, Lumbers ER, and Simonetta G (2002) The cardiovascular and renal effects of acute and chronic inhibition of nitric oxide production in fetal sheep. Exp Physiol 87:343-351.
331. Zanzinger J, Zheng X, and Bassenge E (1994) Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a bradykinin dependent mechanism. Cardiovasc Res 28:209-214.
332. Zarahn ED, Ye X, Ades AM, Reagan LP, and Fluharty SJ (1992) Angiotensin-induced cyclic GMP production is mediated by multiple receptor subtypes and nitric oxide in N1E-115 neuroblastoma cells. J Neurochem 58:1960-1963.
333. 2 receptors in modulating coronary microvascular function. Circ Res 92:322-329.
334. Zhang X, Scicli GA, Xu X, Nasjletti A, and Hintze TH (1997a) Role of endothelial kinins in control of coronary nitric oxide production. Hypertension 30:1105-1111.
335. Zhang X, Xie YW, Nasjletti A, Xu X, Wolin MS, and Hintze TH (1997b) ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation 95:176-182.
336. Zhang X, Xu X, Nasjletti A, and Hintze TH (2000) Amlodipine enhances N production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels. J Cardiovasc Pharmacol 35:195-202.
337. Zhang Z, Rhinehart K, Solis G, Pittner J, Lee-Kwon W, Welch WJ, Wilcox CS, Pallone TL (2005) Chronic ANG II infusion increases NO generation by rat descending vasa recta. Am J Physiol 288:H29-H36.
338. Zhao X, Li X, Trusa S, and Olson SC (2005) Angiotensin type 1 receptor is linked to inhibition of nitric oxide production in pulmonary endothelial cells. Regul Pept 132:113-122.
339. Zheng J, Bird IM, Chen DB, and Magness RR (2005a) Angiotensin II regulation of ovine fetoplacental artery endothelial functions: interactions with nitric oxide. J Physiol (Lond) 565:59-69.
340. Zheng J, Wen Y, Chen DB, Bird IM, and Magness RR (2005b) Angiotensin II elevates nitric oxide synthase 3 expression and nitric oxide production via a mitogens-activated protein kinase cascade in ovine fetoplacental artery endothelial cells. Biol Reprod 72:1421-1428.
341. Zou AP, Wu F, and Cowley AW Jr (1998) Protective effect of angiotensin II-induced increase in nitric oxide in the renal medullary circulation. Hypertension 31:271-276.